Aberdeen, UK – 27 June 2014 – NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company (“NovaBiotics” or the “Company”), today announced that CEO Dr Deborah O’Neil was last night awarded Entrepreneur of the Year Award at the 2014 Grampian Awards for Business Excellence at the Mercure Aberdeen Ardoe House Hotel in Aberdeen.
Dr O’Neil won the Entrepreneur of the Year Award for her outstanding contribution to NovaBiotics, the industry sector and the wider economy. The Award reflects Dr O’Neil as a role model in leadership and her track record of entrepreneurial success.
Professor Gary McEwan, Chief Executive of Enterprise North East Trust (Enterprise) who run the awards, said: “We are delighted to honour Dr Deborah O’Neil as our Entrepreneur of the Year for 2014. Not only is she an innovator in the world of biomedical science, she is admired by her peers and empowers her employees. A true entrepreneur, Deborah works hard, plays hard and gives something back.”
Dr Deborah O’Neil, CEO of NovaBiotics, added: “I am absolutely delighted and honoured to receive The Grampian Entrepreneur of the Year Award. Recognition on this level from the North East business community is fantastic and a tribute to the continued hard work and dedication of all of the NovaBiotics’ team and our work within the local life science sector to translate promising research into a tangible pipeline of anti-infective therapies which address a major health and socioeconomic global concern.”
The Grampian Awards for Business Excellence, which is in its 15th year and hosted by Enterprise North East Trust in 2014, commends enterprise by selecting and rewarding entrepreneurial companies and individuals that are capable of leading the future prosperity of Grampian.
NovaBiotics Ltd is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. A leading innovator in the anti-infectives space, the Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections.
Further information is available at www.novabiotics.co.uk
Issued for and on behalf of NovaBiotics by Instinctif Partners.
To contact the Prosensa team at Instinctif Partners, email email@example.com
Melanie Toyne-SewellManaging Partner